PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.

ABSTRACT:

Background

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer.

Methods

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followe

SUBMITTER: Cercek A 

PROVIDER: S-EPMC9492301 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature